Medpace (NASDAQ: MEDP) and Senestech (NASDAQ:SNES) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.
This is a summary of current ratings and recommmendations for Medpace and Senestech, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Medpace and Senestech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
16.7% of Medpace shares are held by institutional investors. Comparatively, 22.0% of Senestech shares are held by institutional investors. 25.8% of Medpace shares are held by insiders. Comparatively, 27.4% of Senestech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Medpace and Senestech’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Medpace||$421.58 million||2.89||$13.42 million||$0.68||47.74|
Medpace has higher revenue and earnings than Senestech.
Senestech beats Medpace on 6 of the 11 factors compared between the two stocks.
Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.
Receive News & Ratings for Medpace Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.